Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash from Operations (2016 - 2025)

Capricor Therapeutics has reported Cash from Operations over the past 15 years, most recently at 23566743.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 23566743.0 for Q4 2025, down 59.27% from a year ago — trailing twelve months through Dec 2025 was 69811261.0 (down 74.55% YoY), and the annual figure for FY2025 was 69811261.0, down 74.55%.
  • Cash from Operations for Q4 2025 was 23566743.0 at Capricor Therapeutics, down from 19688787.0 in the prior quarter.
  • Over the last five years, Cash from Operations for CAPR hit a ceiling of 24046566.0 in Q1 2022 and a floor of 23566743.0 in Q4 2025.
  • Median Cash from Operations over the past 5 years was 6722161.5 (2022), compared with a mean of 7364811.75.
  • Biggest five-year swings in Cash from Operations: surged 822.26% in 2022 and later crashed 407.2% in 2025.
  • Capricor Therapeutics' Cash from Operations stood at 5627583.0 in 2021, then dropped by 22.65% to 6902052.0 in 2022, then tumbled by 67.98% to 11594052.0 in 2023, then decreased by 27.62% to 14796329.0 in 2024, then crashed by 59.27% to 23566743.0 in 2025.
  • The last three reported values for Cash from Operations were 23566743.0 (Q4 2025), 19688787.0 (Q3 2025), and 20122211.0 (Q2 2025) per Business Quant data.